Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

HKG:2566 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	331.38	348.67	537.63	93.18	71.54	94.83
Short-Term Investments	330.34	365.79	73.75	32.97	44.44	32.97
Cash & Short-Term Investments	661.72	714.47	611.38	126.14	115.98	127.8
Cash Growth	12.76%	16.86%	384.68%	8.76%	-9.25%	-
Accounts Receivable	595.74	601.77	635.8	522.11	454.8	393.98
Other Receivables	-	3.63	2.97	4.14	5.34	14.84
Receivables	595.74	605.4	638.77	526.24	460.14	408.82
Inventory	157.47	155.46	149.12	169.81	171.9	201.53
Other Current Assets	23.44	7.84	10.7	17.54	10.74	9.75
Total Current Assets	1,438	1,483	1,410	839.74	758.76	747.91
Property, Plant & Equipment	420.04	399.84	354.23	373.56	385.8	397.93
Other Intangible Assets	228.77	0.14	0.92	1.05	0.19	0.34
Long-Term Deferred Charges	-	208.36	156.89	90.3	65.6	30.45
Other Long-Term Assets	67.41	26.48	1	3.05	3.24	6.58
Total Assets	2,155	2,118	1,923	1,308	1,214	1,183

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	51.49	49.08	27.64	43.24	52.54	66.85
Accrued Expenses	-	83.01	68.87	66.4	55.32	50.03
Current Portion of Long-Term Debt	80.15	45.49	81.01	130.84	141.53	157.56
Current Portion of Leases	3.12	3.45	0.94	0.77	0.33	0.31
Current Income Taxes Payable	5.89	7.14	14.37	0.44	-	-
Current Unearned Revenue	22.55	22.48	23.6	14.81	16.89	21.21
Other Current Liabilities	172.5	121.75	125.25	91.02	89.31	104.56
Total Current Liabilities	335.7	332.39	341.69	347.52	355.93	400.52
Long-Term Debt	52.24	57.06	38.77	34.52	78.73	45.81
Long-Term Leases	54.17	55.62	-	0.94	-	0.33
Long-Term Unearned Revenue	-	6.2	6.06	7.27	7.56	2.5
Long-Term Deferred Tax Liabilities	16.03	15.48	16.5	19.56	4.84	13.29
Other Long-Term Liabilities	9.44	3	2	-	0.34	2.62
Total Liabilities	467.58	469.74	405.01	409.8	447.4	465.06

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	245.4	245.4	245.4	200	53.45	53.45
Additional Paid-In Capital	-	1,112	1,112	681.43	-	-
Retained Earnings	-	275.43	150.76	12.16	673.73	625.86
Comprehensive Income & Other	1,482	15.15	9.6	4.3	39.01	38.83
Shareholders' Equity	1,687	1,648	1,518	897.89	766.18	718.14
Total Liabilities & Equity	2,155	2,118	1,923	1,308	1,214	1,183

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	189.68	161.62	120.72	167.07	220.58	204
Net Cash (Debt)	472.04	552.85	490.66	-40.93	-104.6	-76.2
Net Cash Growth	18.66%	12.67%	-	-	-	-
Net Cash Per Share	1.94	2.25	2.40	-0.20	-0.52	-0.38
Filing Date Shares Outstanding	240.64	245.4	245.4	200	200	200
Total Common Shares Outstanding	240.64	245.4	245.4	200	200	200
Working Capital	1,103	1,151	1,068	492.22	402.82	347.39
Book Value Per Share	7.01	6.72	6.19	4.49	3.83	3.59
Tangible Book Value	1,458	1,648	1,517	896.84	765.99	717.79
Tangible Book Value Per Share	6.06	6.72	6.18	4.48	3.83	3.59
Buildings	-	280.55	276.41	274.03	271.85	268.73
Machinery	-	329.23	319.44	307.57	290.15	271.78
Construction In Progress	-	10.01	0.24	0.69	1.85	0.36

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 25, 2026

Data Sources Report a data error